Lung cancer: treatment vaccine shows positive results

Lung cancer: treatment vaccine shows positive results

This Monday, September 11, positive results from a French study of a therapeutic vaccine against lung cancer were released.

There is new hope for patients with advanced lung cancer. This Monday, September 11, the French biotech company OSE Immunotherapeutics presented positive results of its therapeutic vaccine Tedopi. They show a lower risk of death compared to chemotherapy.

A total of 219 patients from nine European countries and the United States participated in this study. 139 subjects were given Tedopi, while a comparison group of 80 were on chemotherapy. The vaccine was initially given every three weeks, then every eight weeks for a year, and finally every 12 weeks.

Published in the journal Annals of Oncology, results from a phase 3 study show that “one year after treatment began, 44.1% of these patients were still alive in the vaccine group, compared with only 27.5% in the chemotherapy group.” group.

According to Professor Benjamin Besse, director of clinical research at the Gustave-Roussy Institute and principal investigator of the test called Atalante, the vaccine also causes “fewer side effects” and thus allows “to maintain a better quality of life for patients.” -1.

Study interrupted by pandemic

The goal of cancer vaccines is to train the patient’s immune system to recognize and destroy tumor cells. Tedopi is effective in patients with the HLA-A2 gene, which OSE Immunotherapeutics says is present in half the population.

Due to the Covid-19 pandemic, “the study did not complete recruitment of participants”, Professor Bess said. Thus, it “does not have the desired potency” but still provides insight into “which population group has actually benefited from the vaccine.”

Patients included in the randomized trial had, in fact, previously received chemotherapy and immunotherapy. However, the results showed that Tedopi was most effective for those who initially responded to immunotherapy before relapse.

Hi, I’m laayouni2023